Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Next Previous
Trial Profile

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TOS-358 (Primary)
  • Indications Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Totus Medicines

Most Recent Events

  • 22 Jul 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
  • 22 Jul 2025 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
  • 10 Jan 2025 According to a Totus Medicines media release, company announced Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial in breast, endometrial, urothelial and head and neck cancers at 5 & 8 mg BID.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top